Form 4: Collegium Pharma EVP Sells Shares Under 10b5-1 Plan

David Dieter, EVP & General Counsel of Collegium Pharmaceutical, sold 13,976 shares of common stock under a pre-arranged 10b5-1 trading plan.

Summary

• David Dieter, Executive Vice President & General Counsel of Collegium Pharmaceutical, Inc. (COLL), reported the sale of 13,976 shares of common stock.
• The transaction occurred on March 18, 2026, at a weighted average price of $34.9241 per share.
• The shares were sold in multiple transactions within a price range of $34.74 to $35.39.
• Following this transaction, Mr. Dieter beneficially owns 77,071 shares of Collegium Pharmaceutical common stock.
• The sale was executed pursuant to a Rule 10b5-1 trading plan, which Mr. Dieter adopted on December 5, 2025.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral event. The sale was pre-planned under a Rule 10b5-1 plan, which typically mitigates any negative sentiment associated with insider selling, as it is not reactive to new, material information.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance.

Industry Context

StockSavvy.ai notes that insider sales executed under Rule 10b5-1 trading plans are common practice among corporate executives. These plans allow insiders to pre-arrange sales of company stock at a future date, providing an affirmative defense against claims of insider trading by demonstrating that the transaction was not based on material non-public information. Such pre-scheduled sales are generally viewed as routine and less indicative of management's immediate sentiment about the company's prospects compared to unscheduled, open-market sales.

Stakeholder Impact

• Shareholders: The sale represents a minor reduction in insider ownership, but its pre-planned nature under a 10b5-1 plan suggests it is not indicative of a change in the company's fundamental outlook.

Key Dates

Recommendation

A single insider sale, particularly one executed under a pre-arranged Rule 10b5-1 trading plan, does not typically provide sufficient new information to warrant a change in investment recommendation. Such transactions are often part of an executive's personal financial planning and are not usually indicative of a shift in the company's fundamental value or prospects. Investors should continue to evaluate Collegium Pharmaceutical based on its operational performance, financial results, and strategic initiatives.

Keywords

COLLEGIUM PHARMACEUTICAL, COLL, Form 4, Insider Trading, Stock Sale, David Dieter, 10b5-1 plan